Hiroomi Tada - 14 Sep 2021 Form 3 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Medical Officer
Signature
/s/ John Healy, Attorney-in Fact
Issuer symbol
TYRA
Transactions as of
14 Sep 2021
Net transactions value
$0
Form type
3
Filing time
14 Sep 2021, 21:14:52 UTC
Next filing
04 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TYRA Common Stock 77,922 14 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TYRA Stock Option (Right to Buy) 14 Sep 2021 Common Stock 126,246 $0.6100 Direct F2
holding TYRA Stock Option (Right to Buy) 14 Sep 2021 Common Stock 134,937 $2.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 77,922 shares subject to repurchase by us, which are subject to vesting.
F2 25% of the shares subject to the option will vest on November 9, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F3 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney